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   Transcription of a proto-oncogene 
c-fos is induced rapidly to high levels by 
various extracellular stimuli.  To explore 
the molecular mechanism of c-fos gene 
induction, we established a defined in vitro 
transcription system for the c-fos 
promoter that consists of purified 
activators (SRF, Elk-1, CREB and ATF1), 
general transcription factors (GTFs) and 
RNAP II.  In this reconstituted 
transcription system, activation of c-fos 
transcription was highly dependent upon 
coactivators such as PC4 and Mediator, 
indicating a very weak activation potential 
of the activators in the context of an 
unaltered promoter structure.  This 
heightened coactivator-dependency, 
however, allowed us to identify from HeLa 
nuclear extract a coactivator-like activity 
termed transcriptional regulator of c-fos 
(TREF) that enhanced c-fos transcription 
but not GAL4-VP16-dependent 
transcription.  TREF cooperated with 
Mediator to enhance c-fos transcription by 
~60 fold over its basal level, and like 
Mediator, stimulated 
activator-independent (basal) 
transcription as well.  Further 
purification of TREF revealed that it 
consists of at least three distinct 
components, one of which was purified to 
near homogeneity and identified as 
heterogeneous nuclear ribonucleoportein 
R (hnRNP R).  Recombinant hnRNP R 
enhanced transcription from the c-fos 
promoter and displayed cooperativity with 
PC4 and Mediator, thus demonstrating its 
direct transcriptional activity.   
 
   The c-fos promoter is one of the very well 
studied gene promoters and responds in a 
rapid and transient manner to a myriad of 
extracellular signals such as growth factors, 
cytokines and cellular stress (1).  These 
signals are transmitted via cascades of 
kinases including mitogen-activated protein 
(MAP) kinases to the nucleus, wherein the 
transcription factors bound on the inducible 
cis-elements are activated upon 
phosphorylation (2).  Among the important 
cis-elements within the c-fos promoter are the 
serum response element (SRE) upon which a 
dimer of SRF and one molecule of Elk-1 
form a ternary complex (3) and the cAMP 
response elements (CREs) which are bound 
by a heterodimer of CREB and ATF1 (4).  
Although the signal transduction and the 
subsequent regulation of the activators are 
well characterized, much less is known about 
the mechanism by which the activators elicit 
dramatic c-fos induction. 
   Transcription of a typical protein-coding 
gene such as c-fos requires general 
transcription factors (GTFs), including TFIIA, 
TFIIB, TFIID, TFIIE, TFIIF and TFIIH, 
which form the preinitiation complex (PIC) 
with RNA polymerase II (RNAP II) on the 
promoter (5).  PIC formation and the 
following steps of transcription are ultimate 
targets of activators, whose activating signals 
are transduced to GTFs and RNAP II in a 
process that is poorly understood.  This 
process, nonetheless, has been shown to 
require another class of cofactors termed 
coactivators or coregulators that serve as a 
physical and functional bridge between 
activators and GTFs (6,7).  In the case of 
the c-fos gene, well-characterized p300/CBP 
serves as a coactivator for SRF (8), Elk-1 (9) 
and CREB (10,11), and coactivates 
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transcription not only as a bridging factor but 
also as a histone acetyltransferase (12).  
More recent studies indicate that another type 
of coactivator termed Mediator is also 
involved in c-fos transcription.  The Med23 
subunit of Mediator, first identified as an 
E1A-interacting protein (13), has been 
demonstrated to interact with Elk-1 and plays 
a role for SRE-mediated transcriptional 
activation (14).  Indeed, Med23 (-/-) 
knockout cells show reduced transcription of 
SRE-containing genes such as egr-1 and 
c-fos (14,15). 
   Mediator was initially discovered by the 
genetic and biochemical analyses in yeast 
(16-18).  Subsequent biochemical dissection 
of mammalian nuclear extracts by several 
independent groups lead to the purification of 
mammalian Mediator complexes (6), 
variously named as negative regulator of 
activated transcription (NAT), the mouse 
Mediator complex, thyroid hormone 
receptor-associated proteins (TRAP), 
SRB-MED-containing cofactor (SMCC), 
vitamin D receptor-interacting proteins 
(DRIP), activator-recruited cofactor (ARC), 
cofactor required for Sp1 activation (CRSP), 
positive cofactor 2 (PC2).  The identified 
complexes turned out to be highly related to 
each other and probably constitute the 
identical Mediator or its various 
subcomplexes (6). 
   Given the diversity of the employed 
biochemical systems, it is somewhat 
surprising that only the requirement of 
Mediator was eventually revealed.  The 
apparent unity, however, could be due to the 
use of artificially constructed activators and 
templates that may alter, or even obviate, the 
requirement of some cofactors.  Indeed, for 
producing sufficiently strong signals of 
transcript, in vitro transcription systems 
typically utilize a strong activation domain 
fused to a DNA-binding domain (often the 
DNA binding domain of yeast GAL4) and an 
artificially constructed model promoter with 
tandem repeats of activator-binding sites.  
Because of the activator’s intrinsically strong 
activation potential and the optimized 
geometry of activator-binding sites, it is 
possible that these systems obscure the 
requirement for some class of cofactors. 
   To identify a novel cofactor requirement 
in an unbiased manner, we chose the c-fos 
promoter as a model and initiated to 
recapitulate transcription from the 
naturally-configured promoter with only 
purified components.  We employed a 
defined in vitro transcription system using 
purified GTFs (19), together with SRF, Elk-1, 
CREB and ATF1 to analyze transcriptional 
activation from the c-fos promoter that 
retains cis-elements in its original 
configuration.  Unlike the 
GAL4-VP16-based model promoter, 
activation of the c-fos promoter by SRF, 
Elk-1, CREB and ATF1 was much more 
dependent on coactivators such as PC4 and 
Mediator.  This heightened 
coactivator-dependency allowed us to 
identify from HeLa nuclear extract a novel 
coactivator-like activity termed 
transcriptional regulator for c-fos (TREF), 
which augments activated transcription from 
the c-fos promoter but not the 
GAL4-VP16-dependent transcription.  
Upon further purification, TREF was 
separated into three activities, one of which 
was identified as hnRNP R.  Recombinant 
hnRNP R stimulated c-fos transcription and 
cooperated with PC4 and Mediator, evoking 
a potent activation (~100-fold) of the c-fos 
promoter over its basal level.  Since hnRNP 
R is a presumptive RNA binding protein and 
is possibly involved in regulating mRNA 
stability, our results suggest a potential link 
between transcription and the subsequent 
posttranscriptional processes for rapid and 
transient c-fos induction. 
 
EXPERIMENTAL PROCEDURES 
 
Construction of baculoviruses for expressing 
FLAG-tagged proteins— Complementary 
DNAs (cDNAs) of human SRF, Elk-1, CREB, 
ATF1 and hnRNP R were isolated from HeLa 
1st-strand cDNA by a PCR-based method.  
Since the 5’ region of SRF cDNA could not 
be amplified by PCR due to a high GC 
content, ~300 bp of the 5’ region was 
constructed by annealing synthetic 
oligonucleotides based on the published SRF 
DNA sequence.  PCR was used to add NdeI 
and BamHI sites to the N- and C-terminal 
ends of each cDNA, and when necessary, 
internal NdeI and BamHI sites were mutated 
without altering the amino acid sequences.  
Each cDNA was sequenced in its entirety and 
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then subcloned into a modified baculovirus 
transfer vector pTOF, which was constructed 
from its parental plasmid, pVL1392, by 
mutating the unique NdeI site within the 
plasmid and adding FLAG-encoding DNA 
sequence as well as NdeI and BamHI sites.  
Recombinant baculoviruses were prepared by 
transfection of Sf9 cells with each transfer 
vector (1.0 µg), linearized bacuroviral DNA 
(0.25 µg) and cellfectin (Invitrogen), and the 
obtained viruses were plaque purified and 
amplified. 
Preparation of High Five cell extract— High 
Five cells were infected with each amplified 
baculovirus and cultured at 27oC for 50 hours.  
The collected cells were washed once with 
PBS, resuspended in one packed cell volume 
(PCV) of hypotonic buffer (10 mM Tris-HCl, 
pH 7.3 at 4oC, 1.5 mM MgCl2, 10 mM KCl) 
containing 0.5 mM PMSF, 1 mM DTT, 100 
nM MG132, 10 mM β−glycerophosphate and 
protease inhibitor cocktail (Sigma) and then 
homogenized mildly in a dounce 
homogenizer.  After centrifugation, the 
supernatant was saved as the cytoplasmic 
(S100) fraction and the pellet (crude nuclei) 
was suspended in one PCV of low salt buffer 
(10 mM Tris-HCl, pH 7.3 at 4oC, 25% 
glycerol, 0.2 mM EDTA, 1.5 mM MgCl2, 10 
mM KCl) and extracted by addition of one 
PCV of high salt buffer (10 mM Tris-HCl, 
pH 7.3 at 4oC, 25% glycerol, 0.2 mM EDTA, 
1.5 mM MgCl2, 1.2 M KCl).  The nuclear 
suspension was fractionated by centrifugation 
into the nuclear extract and nuclear pellet 
fractions. 
Purification of F:SRF, F:Elk-1, F:CREB, 
F:ATF1 and F:hnRNP R— FLAG-tagged 
SRF (F:SRF)-containing S100 fraction was 
loaded onto HiTrap heparin (GE Healthcare) 
equilibrated with BC(100) containing 0.5 
mM PMSF and 1 mM DTT.  BC buffer 
consists of 20 mM Hepes-KOH, pH 7.9, 1 
mM EDTA and 10% glycerol, and the 
number in a parenthesis shows its KCl 
concentration (mM).  The bound proteins 
were eluted with a 10 CV (column volume) 
linear gradient from 100 to 1000 mM KCl.  
F:SRF bound to HiTrap heparin was eluted at 
300~500 mM KCl.  The fractions 
containing F:SRF were adjusted to 100 mM 
with BC(0) and loaded onto HiTrap Q (GE 
Healthcare), and the bound proteins were 
eluted with a 10 CV linear gradient from 100 
to 1000 mM KCl.  F:SRF was eluted at 
200~300 mM KCl, and the fractions 
containing F:SRF were loaded onto Mono S.  
F:SRF bound to Mono S was eluted at 
150~250 mM KCl.  F:Elk-1 was purified 
with the same columns as those used for 
F:SRF (HiTrap heparin, HiTrap Q and Mono 
S).  F:Elk-1 was eluted at 200~300 mM KCl 
from HiTrap heparin and was in the 
flow-through fractions from both HiTrap Q 
and Mono S.  The High Five S100 fraction 
containing recombinant F:CREB (CREBα 
isoform) was loaded onto HiTrap SP (GE 
Healthcare) equilibrated with BC(100) 
containing 0.5 mM PMSF.  F:CREB bound 
to HiTrap SP was eluted stepwise with 
BC(700).  The eluate was dialyzed against 
BC(100) containing 0.5 mM PMSF and 0.1% 
Triton X-100, and F:CREB was further 
purified with anti-FLAG M2 agarose.  The 
same method was also used for purifying 
F:ATF1.  F:hnRNP R was purified similarly 
by SP Sepharose and Q Sepharose columns, 
followed by affinity purification using 
anti-FLAG M2 agarose. 
GST pull-down assays— GST pull-down 
assays were performed essentially as 
described (19) using a FLAG-tagged PC4 
expressed in E. coli. 
In vitro transcription— The promoter region 
of the c-fos gene (from -380 to -10) was 
isolated from human genomic DNA by PCR 
using the following primers; 
5’-GGCCGAATTCGCACTGCACCCTCGG
TGTTG-3’ and 
5’-GGCCGTCGACGGCCGCGCCGCAGC
CACTGCTTTTATAAC-3’. 
After disruption of the EagI site at -121, the 
c-fos promoter fragment was subcloned 
between EcoRI and SalI sites of pUC19, and 
the G-less cassette from pG5HMC2AT (20) 
was fused to the c-fos promoter by using an 
EagI site introduced at -8.  In vitro 
transcription assays were performed as 
described (21). 
Purification of Mediator— To produce a 
3xFLAG-Nut2-expressing cell line, 
pLNCX2-3xFLAG-Nut2 was introduced into 
AmphoPack-293 cells by Lipofectin 
(Invitrogen) and the produced viruses were 
used to infect HeLa S3 cells, which were 
then selected in 0.8 mg/ml G418 medium 
containing 10% FBS and 1% 
penicillin-streptomycin solution (GIBCO).  
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The G418-resistent colony that expressed the 
highest level of 3xFLAG-Nut2 was expanded 
for nuclear extract preparation.  The nuclear 
extract was fractionated on a P11 column, 
and the resulting 0.85 M KCl eluate was 
adjusted to BC(300) containing 0.1% Triton 
X-100 and mixed with M2-agarose (Sigma) 
at 4oC for 1hr.  After extensive washes with 
the same buffer, bound proteins were eluted 
with the buffer containing 0.1 mg/ml 
3xFLAG peptide. 
HeLa NE fractionation— Fifty ml of HeLa 
nuclear extract (~10 mg/ml protein) was 
adjusted to BC(100) and loaded onto a 50-ml 
P11 column, and the flow-through fraction 
was collected as fraction A.  The bound 
proteins were then eluted stepwise in 
BC(300), BC(500) and BC(850), and the 
eluates were collected as fractions B, C and 
D, respectively.  Each fraction was then 
adjusted to BC(100) by dialysis and loaded 
onto an appropriate volume (~10 ml per 100 
mg protein) of DE52 column, and the 
flow-through fraction and the BC(300) eluate 
were collected. 
 
RESULTS 
 
Expression and purification of natural 
activators for the c-fos gene— The c-fos 
promoter contains binding sites for several 
transcription factors, including serum 
response factor (SRF), Ets-related 
transcription factor (Elk-1), cAMP-response 
element binding protein (CREB) and 
activating transcription factor 1 (ATF1).  
SRF binds the serum response element (SRE) 
as a dimer and forms a ternary complex with 
Elk-1, and CREB binds the c-fos AP-1 site 
(FAP-1) and cAMP-response element (CRE) 
either as a homodimer or as a heterodimer 
with ATF1 (Fig. 1A).  These transcription 
factors play important roles for c-fos 
transcription, with each transcription factor 
differentially regulated by extracellular 
signals (22).  The activities of SRF, Elk-1, 
CREB and ATF1 are enhanced upon 
phosphorylation by MAP kinases or their 
downstream effector kinases such as the 
mitogen- and stress-activated kinases 
(MSKs) and the ribosomal S6 kinases 
(RSKs) (23). 
   As a first step to better understand the 
regulatory mechanisms of c-fos transcription 
in vitro, it was essential to obtain intact SRF, 
Elk-1, CREB and ATF1.  For this purpose, 
we chose the baculovirus expression system, 
which can provide posttranslational 
modifications as opposed to the E. coli 
system, because these transcription factors 
are subject to multiple posttranslational 
modifications, including phosphorylation, 
glycosylation and sumoylation that regulate 
their activity and stability (24,25).  
Moreover, to prevent rapid degradation of the 
expressed proteins, we found that the 
inclusion of a proteasome inhibitor MG132 
during purification was crucial, presumably 
because of the ubiquitination and 
proteasome-mediated protein degradation 
(26).  As shown in Fig. 1B, the expressed 
activators were purified through 
combinations of conventional and affinity 
columns.  Specifically, SRF and Elk-1 were 
purified by HiTrap heparin, HiTrap Q and 
Mono S columns, while CREB and ATF1 
were purified by a HiTrap SP column and 
then by anti-FLAG M2 affinity purification.  
The SDS-PAGE analysis showed that the 
obtained activators were essentially 
homogenous with no apparent degradation 
(Fig. 1C). 
   The purified transcription factors were 
also tested for their DNA-binding using 
gel-shift (supplemental Fig. S1) and DNase I 
footprinting assays (supplemental Fig. S2).  
As expected, SRF and Elk-1 bound 
specifically to the SRE, and CREB and ATF1 
bound to both the FAP-1 and CRE.  Elk-1 
binding to the SRE was completely 
dependent upon the presence of SRF.  Both 
CREB and ATF1 bound to the FAP-1 and 
CRE as either homodimer or heterodimer; 
however, a heterodimer of CREB and ATF1 
appeared to show the strongest binding.  
Together, the purified recombinant SRF, 
Elk-1, CREB and ATF1 are intact and retain 
the binding activity to their cognate 
cis-elements. 
 
SRF, Elk-1, CREB and ATF1 fail to activate 
transcription in the reconstituted in vitro 
transcription system— Having confirmed the 
DNA binding activities of recombinant SRF, 
Elk-1, CREB and ATF1, we then tested their 
transcriptional activities.  First, to reveal the 
intrinsic activation potential of these cellular 
activators, we employed an in vitro 
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transcription system reconstituted only with 
RNAP II and six GTFs (TFIIA, TFIIB, TFIID, 
TFIIE, TFIIF and TFIIH).  The reconstituted 
in vitro transcription system was devoid of 
any known coactivators but capable of 
supporting activated transcription by 
GAL4-VP16 (19).  A c-fos template, 
pfMC2AT, was constructed by replacing the 
upstream GAL4-biding sites and the TATA 
box of pG5HMC2AT with the c-fos promoter 
region (Fig. 2A).  Thus, the pfMC2AT 
template encompasses from -380 to -10 of 
the human c-fos gene, including the SRE, 
FAP-1, CRE and TATA box, which allows 
simultaneous binding of seven activators; 
namely, one Elk-1 and two SRFs to the SRE, 
and each CREB/ATF1 heterodimer to the 
FAP-1 and CRE (Fig. 1A). 
   Consistent with the previous results, the 
reconstituted transcription system allowed 
GAL4-VP16 to activate transcription from its 
cognate template with five GAL4-binding 
sites (pG5HMC2AT) in the absence of any 
coactivator, achieving ~2 to 3-fold activation 
at its saturating amount (Fig. 2D) (19).  The 
same transcription system, however, failed to 
activate transcription when one of the c-fos 
gene activators (SRF, Elk-1, CREB and 
ATF1) was added individually (Fig. 2B).  
Moreover, even when various combinations 
of the activators (SRF/Elk-1, CREB/ATF1 or 
SRF/Elk-1/CREB/ATF1) were tested, 
minimal levels of activation was observed 
(Fig. 2C).  At the highest amounts of the 
four activators, where c-fos transcription 
increased apparently, basal (i.e. 
activator-independent) transcription also 
increased to similar extents, indicating no net 
effect on activator-dependent transcription 
under these conditions (Fig. 2C, lanes 9 and 
10).  Given that a single c-fos promoter 
binds seven activators (Fig. 1A), with each 
activator possessing at least one activation 
domain, it is unlikely that the number of 
activators or activation domains is 
insufficient for c-fos promoter activation.  
Thus, unlike viral activators (e.g. VP16), 
which can activate transcription in the 
absence of any coactivator, the tested 
activators (SRF, Elk-1, CREB and ATF1) 
alone are insufficient to evoke activated 
transcription, suggesting a higher degree of 
dependence on coactivators. 
 
A coactivator PC4 permits transcriptional 
activation of the c-fos promoter by SRF, Elk-1, 
CREB and ATF1— As an initial step to 
explore their coactivator requirement for 
activating the c-fos promoter, we tested the 
effect of PC4, a well-characterized 
coactivator that augments in vitro 
transcription for a wide variety of activators 
(27,28).  We added PC4 to in vitro 
transcription reactions, in which various 
combinations of the c-fos activators were 
examined.  Consistent with our earlier study 
(19), PC4 enhanced GAL4-VP16-dependent 
transcription from 2.5-fold to 38 fold, giving 
rise to additional increase (over 10 fold) in 
activation (Fig. 3C).  Similarly, PC4 enabled 
the c-fos activators individually (Fig. 3A) or 
as combinations of SRF/Elk-1, CREB/ATF1 
or SRF/Elk-1/CREB/ATF1 (Fig. 3B), to 
activate transcription by ~5-9 fold.  Thus, 
SRF, Elk-1, CREB and AFT1 are indeed 
capable of activating transcription, though in 
a markedly PC4-dependent manner. 
   PC4 exerts its coactivator activity by 
mediating interactions between activators and 
GTFs such as TFIIA (27), TFIIB (29) and 
TFIIH (19).  Given the ability of PC4 to 
enhance the transcriptional activities of SRF, 
Elk-1, CREB and ATF1 (Fig. 3, A, B and C), 
we wished to know if PC4 could interact with 
these activators.  To determine this, we 
performed GST pull-down assays using 
GST-fused activators and FLAG-tagged PC4.  
Figure 3D shows that PC4 interacted strongly 
with CREB and Elk-1, moderately with ATF1, 
and very weakly with SRF.  The results 
indicate that these interactions may, at least 
in part, provide a mechanistic basis for 
PC4-enhanced transcriptional activities of 
SRF, Elk-1, CREB and ATF1. 
 
A novel activity enhances in vitro 
transcription from the c-fos promoter— The 
numerous in vivo studies have shown that 
various extracellular stimuli elicit c-fos gene 
activation that typically reaches well over a 
hundred fold.  Thus, even in the presence of 
PC4, the observed activation of the c-fos 
promoter in vitro (Fig. 2, A and B) was 
unremarkable as compared to that generally 
observed within cells.  To further explore 
the coactivator requirement for the c-fos 
promoter in an unbiased manner, we 
fractionated the nuclear extract from rapidly 
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growing HeLa cells into eight fractions (Fig. 
4A) and examined their effects on c-fos 
transcription in vitro. 
   As expected, the D0.3 fraction, which 
contains TFIID (supplemental Fig. S3), 
increased both basal and activated 
transcription (Fig. 4B, lanes 17 and 18), as 
the amount of TFIID in the current 
transcription system was set below the 
saturating amount to reveal the effect of 
activators (Fig. 4C, lanes 7-10).  
Furthermore, the D0.1 fraction showed an 
activity reminiscent of Mediator (Fig. 4B, 
lanes 15 and 16) (30), indicating that the 
D0.1 activity is, at least in part, attributable 
to Mediator, though the presence of 
additional coactivators cannot be excluded.  
Intriguingly, the A0.3 fraction, in which no 
biochemically defined coactivator had been 
reported, stimulated transcription from the 
c-fos promoter (Fig. 4B, lanes 5 and 6).  
Although this fraction includes TFIIA (31), 
which is important for activated transcription 
in vitro (19), further addition of TFIIA did 
not affect the level of c-fos transcription at all 
(Fig. 4C, lanes 3-6), thus excluding the 
possibility that the observed stimulatory 
effect was due to TFIIA.  Collectively, our 
biochemical analyses identified a novel 
activity, which we termed TREF 
(Transcriptional REgulator of c-Fos), that can 
stimulate in vitro transcription from the c-fos 
promoter. 
 
TREF enhances transcription from the c-fos, 
but not the 5xG promoter and displays 
cooperativity with Mediator— We then 
addressed whether or not TREF was specific 
to the c-fos promoter.  As shown in Fig. 5A, 
TREF increased both basal transcription 
(lane 3) and activator-dependent transcription 
(lane 4) from the c-fos promoter, eliciting a 
~17-fold net increase of transcription from 
the basal level (compare lanes 1 and 4).  
However, while TREF increased basal 
transcription from the 5xG promoter, it 
somewhat diminished 
GAL4-VP16-dependent transcription from 
the same promoter (Fig. 5A, lanes 9 and 10).  
Thus, although TREF enhances transcription 
through the core promoter as well as the 
upstream regulatory elements, the 
stimulatory effect of TREF through the 
upstream elements appears to have some 
activator specificity.  By contrast, the D0.1 
fraction, which principally reflects the 
activity of Mediator, stimulated both basal 
and activator-dependent transcription from 
the c-fos (Fig. 5A, lanes 5 and 6) and 5xG 
promoters (Fig. 5A, lanes 11 and 12) in a 
similar manner.  Finally, the fully 
phosphorylated activators and its 
unphosphorylated (i.e. 
phosphorylation-defective) mutants displayed 
essentially indistinguishable response to 
TREF, indicating that phosphorylation of the 
activators do not affect the TREF activity 
(data not shown). 
   Next, we tested the functional 
cooperativity of TREF and Mediator, a major 
coactivator component of the D0.1 fraction, 
in stimulating c-fos transcription.  As shown 
in Fig. 5C, both TREF and Mediator, which 
was isolated from HeLa cell line stably 
expressing FLAG-Nut2 (Fig. 5B), enhanced 
activator-dependent transcription from the 
c-fos promoter (lanes 4, 6, 12 and 14).  
When TREF and Mediator were added 
simultaneously to the transcription reactions, 
they displayed further enhancement of 
transcription from the c-fos promoter, 
resulting in ~60 fold net activation (Fig. 5C, 
lanes 8 and 16) over the basal levels (Fig. 5C, 
lanes 1 and 9).  Importantly, this 
cooperativity between TREF and Mediator 
was observed in the range of amounts where 
2-fold increase of TREF (Fig. 5C, compare 
lanes 3 and 4 versus 11 and 12) or 3-fold 
increase of Mediator (Fig. 5C, compare lanes 
5 and 6 versus 13 and 14) had little additional 
effect on transcription individually.  Thus, 
TREF not only stimulates c-fos transcription 
through the core promoter and the upstream 
regulatory elements, but also displays 
cooperativity with Mediator for enhancing 
c-fos transcription, indicating that the c-fos 
gene may require multiple coactivators for its 
dramatic level of transcriptional activation 
observed in vivo. 
 
hnRNP R is an active component of TREF— 
To further characterize the TREF activity, we 
purified the A0.3 fraction using c-fos 
transcription assays with SRF, Elk-1, CREB 
and ATF1 as activators and PC4 as a 
coactivator.  Our initial attempt to purify 
TREF resulted in a dramatic reduction in the 
TREF activity; however, we realized that the 
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reduced activity was due to the separation of 
the original TREF activity into different 
fractions.  Indeed, as shown in Fig. 6A, 
purification with a larger amount of the A0.3 
fraction by Q Sepharose and Heparin 
Sepharose showed that the TREF activity 
could be separated into at least three 
activities that were tentatively designated as 
TREFα, TREFβ and TREFγ.  TREFα was 
purified further to near homogeneity by a 
Mono S column, and SDS-PAGE analysis 
revealed that active fractions contained a 
~80-kDa protein as a major polypeptide that 
correlated with the TREFα activity (Fig. 6B).  
Mass spectrometric analysis identified this 
80-kDa polypeptide as hnRNP R, a putative 
RNA-binding protein, whose function 
remains ill defined.  hnRNP R is a 633-aa 
protein with three RRMs and one 
arginine-glycine-glycine rich (RGG) box, and 
belongs to a group of proteins termed 
hnRNPs (32) (Fig. 6C). 
   To demonstrate that hnRNP R possesses 
the TREFα activity, we expressed 
recombinant hnRNP R by baculovirus 
expression system and purified it to 
homogeneity (Fig. 6D).  As shown in Fig. 
6D, recombinant hnRNP R displayed a 
coactivator activity in a dose-dependent 
manner in the presence of PC4.  The effect 
of hnRNP R on GAL4-VP16-dependent 
transcription, however, was minuscule 
(supplemental Fig. S4), indicating that its 
coactivator activity varies depending upon 
the used activators.  When PC4, Mediator 
and hnRNP R were tested individually or in 
combination, each coactivator stimulated 
c-fos transcription by 4 to 12 fold.  hnRNP 
R and Mediator also stimulated 
activator-independent transcription to similar 
extents, indicating that both of them act 
directly to the core promoter in the absence 
of activators.  Similar to the activity of a 
more crude TREF fraction (i.e. A0.3), hnRNP 
R also showed cooperativity with PC4 and 
Mediator, (Fig. 6D), and the combined effect 
of the three coactivators on 
activator-dependent c-fos transcription 
reached well over 100 fold (Fig. 6E).  
Together, our results indicate that hnRNP R 
serves as a transcriptional coactivator for 
c-fos transcription. 
 
 
DISCUSSION 
 
   In this study, we have established an in 
vitro transcription system that utilizes 
unaltered cellular activators (SRF, Elk-1, 
CREB and ATF1) and the natural c-fos 
promoter to explore its coactivator 
requirement in an unbiased manner.  We 
have identified from HeLa nuclear extract a 
novel coactivator activity, termed TREF, that 
specifically augments transcription from the 
c-fos promoter and cooperates with Mediator.  
TREF appears to be composed of at least 
three activities, one of which was identified 
as hnRNP R.  Recombinant hnRNAP R 
stimulated transcription from the c-fos 
promoter and cooperated with PC4 and 
Mediator to elicit a high level of c-fos 
activation. 
 
Functional distinction between viral and 
cellular transcription factors— Our 
transcription assays showed that the tested 
cellular activators fail to activate 
transcription in the absence of any 
coactivator, a condition under which the 
archetypical transcriptional activator 
GAL4-VP16 can still activate transcription.  
Viral activators such as VP16, E1A, Tax and 
pX typically do not bind DNA directly but 
piggyback on DNA-bound cellular activators 
to enhance gene expression (33).  For 
example, a prototypical viral protein VP16 
becomes tethered to DNA by forming a 
complex with Oct-1 and HCF, and then 
interacts with GTFs (TBP, TAFs, TFIIB and 
TFIIH) (34).  Similarly, another viral 
protein pX is recruited to DNA via its 
interactions with transcriptional activators 
and then activate transcription through 
interactions with TBP, TFIIB and TFIIH 
(35,36).  Given these properties, viral 
activators resemble a coactivator rather than 
a mere transcriptional activator. 
   Besides acting as a coactivator, viral 
activators may have usurped part of the 
TFIID function as well.  For example, the 
SV40 large T antigen (37), the hepatitis B 
viral protein pX (38) and the human 
cytomegalovirus IE proteins (39) can 
functionally obviate the requirement of TAF1, 
a TFIID subunit that functions as a 
coactivator.  Thus, viral activators in general 
may depend less on coactivators than the 
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cellular activators.  This would allow viral 
activators to maximize their transcriptional 
potency in a manner detached from cellular 
regulatory networks.  Cellular activators, by 
contrast, may retain their regulatory potential 
at the cost of activation potency, possibly 
necessitating a greater dependency on 
coactivators. 
 
hnRNP R possesses a coactivator activity for 
the c-fos promoter— The current study has 
identified a novel type of coactivator, termed 
TREF, that stimulates transcription from the 
c-fos promoter in vitro and is apparently 
distinct from the more generally required 
Mediator (40).  The TREF activity increases 
activator-dependent as well as basal 
transcription from the c-fos promoter in a 
manner similar to that of Mediator (18,41,42).  
Unlike Mediator, however, TREF does not 
stimulate GAL4-VP16 dependent 
transcription in vitro.  Together with its 
cooperativity with Mediator in stimulating 
transcription from the c-fos promoter and its 
differing chromatographic behavior from 
Mediator (30,43), TREF appears to be a 
novel activity distinct from the 
well-characterized Mediator.  Indeed, 
several steps of chromatography revealed that 
TREF is separated into three distinct 
components, and one of which, TREFα, 
turned out to be hnRNP R.  As it is, TREFα 
is also distinct from the reported coactivators 
for SRF or CREB, including CoS 
(coactivator for SRF-activated transcription) 
(44), MRTFs (myocardin-related 
transcription factors, (45,46), CBP (CREB 
binding protein)/p300 (47) and TORC 
(transducer of regulated CREB) (48,49). 
   hnRNP R belongs to a group of diverse 
RNA-binding proteins termed heterogeneous 
nuclear ribonucleoproteins (hnRNPs), which 
are characterized by RNA binding motifs 
such as the RGG box, RRM and KH domains 
(50).  hnRNPs are involved in a wide array 
of RNA metabolism including transcription, 
splicing, RNA export, RNA stability and 
translation (50).  No specific function, 
however, has been assigned to hnRNP R 
except for a recent report that suggests its 
role in ARE-mediated RNA degradation (51).  
Most of hnRNPs that have been analyzed so 
far do not appear to affect transcription (50); 
however, several lines of evidence indicate 
that hnRNP K serves as a transcription factor.  
Indeed, hnRNP K binds to a C-rich DNA 
sequence termed the CT-element, which is 
located upstream of the c-myc gene, and 
interacts directly with TBP (52).  Moreover, 
hnRNP K has been demonstrated to activate 
transcription in vitro and in vivo (52).  
Although hnRNAP R is structurally unrelated 
to hnRNP K, which has three KH domains 
but no RRM or RGG box (53), our 
purification and functional analyses of 
TREFα indicate that hnRNP R is another 
member of hnRNPs that directly stimulate 
transcription in addition to its possible role in 
regulating mRNA stability (51). 
   Recent studies have revealed that in 
addition to stimulating transcription, some 
coactivators participate actively in 
posttranscriptional processes.  For example, 
the thermogenic coactivator PGC-1 regulates 
alternative splicing of the transcript from the 
gene promoter on which it is loaded (54).  
This coupling of transcription and splicing 
requires the RRM and serine- and 
arginine-rich (SR) domain within PGC-1 (54), 
indicating the importance of RNA-binding 
domains for the coupling.  A coactivator for 
nuclear receptors, CoAA, also influences 
alternative splicing of the transcript in a 
steroid hormone-specific manner (55).  
CoAA contains two RRMs and is structurally 
an hnRNP-like protein (56).  Thus, a subset 
of diverse proteins with RNA-binding 
domains such as the RRM, KH domain, SR 
domain and/or RGG box may be actively 
involved in both transcription and 
posttranscriptional processes. 
   The mechanism by which hnRNP R 
stimulates c-fos transcription awaits future 
studies.  However, given that hnRNP R is 
found among the proteins associated with 
phosphorylated CTD (57) and thereby 
presumed to be complexed with elongating 
RNAP II, one attractive hypothesis is that 
hnRNP R stimulates RNAP II elongation, 
perhaps through its interactions with 
phosphorylated CTD and with transcribed 
RNA.  If so, CTD phosphorylation by 
TFIIH and/or p-TEFb might regulate the 
binding of hnRNP R to the CTD and alter its 
coactivator activity.  All in all, our results 
support the emerging view that transcription 
is tightly coupled to the subsequent RNA 
metabolism. 
 9 
REFERENCES 
1. Treisman, R. (1995) EMBO J. 14, 4905-4913 
2. Cahill, M. A., Janknecht, R., and Nordheim, A. (1996) Curr. Biol. 6, 16-19 
3. Price, M. A., Hill, C., and Treisman, R. (1996) Philos. Trans. R. Soc. Lond. B Biol. Sci. 
351, 551-559 
4. Wang, Y., and Prywes, R. (2000) Oncogene 19, 1379-1385 
5. Roeder, R. G. (1996) Trends Biochem. Sci. 21, 327-335 
6. Malik, S., and Roeder, R. G. (2000) Trends Biochem. Sci. 25, 277-283 
7. Lewis, B. A., and Reinberg, D. (2003) J. Cell. Sci. 116, 3667-3675 
8. Ramirez, S., Ait-Si-Ali, S., Robin, P., Trouche, D., and Harel-Bellan, A. (1997) J. Biol. 
Chem. 272, 31016-31021 
9. Janknecht, R., and Nordheim, A. (1996) Biochem. Biophys. Res. Commun. 228, 831-837 
10. Kwok, R. P., Lundblad, J. R., Chrivia, J. C., Richards, J. P., Bachinger, H. P., Brennan, 
R. G., Roberts, S. G., Green, M. R., and Goodman, R. H. (1994) Nature 370, 223-226 
11. Arany, Z., Sellers, W. R., Livingston, D. M., and Eckner, R. (1994) Cell 77, 799-800 
12. Ogryzko, V. V., Schiltz, R. L., Russanova, V., Howard, B. H., and Nakatani, Y. (1996) 
Cell 87, 953-959 
13. Boyer, T. G., Martin, M. E., Lees, E., Ricciardi, R. P., and Berk, A. J. (1999) Nature 399, 
276-279 
14. Stevens, J. L., Cantin, G. T., Wang, G., Shevchenko, A., and Berk, A. J. (2002) Science 
296, 755-758 
15. Wang, G., Balamotis, M. A., Stevens, J. L., Yamaguchi, Y., Handa, H., and Berk, A. J. 
(2005) Mol. Cell 17, 683-694 
16. Kelleher, R. J., 3rd, Flanagan, P. M., and Kornberg, R. D. (1990) Cell 61, 1209-1215 
17. Flanagan, P. M., Kelleher, R. J., 3rd, Sayre, M. H., Tschochner, H., and Kornberg, R. D. 
(1991) Nature 350, 436-438 
18. Kim, Y. J., Bjorklund, S., Li, Y., Sayre, M. H., and Kornberg, R. D. (1994) Cell 77, 
599-608 
19. Fukuda, A., Nakadai, T., Shimada, M., Tsukui, T., Matsumoto, M., Nogi, Y., 
Meisterernst, M., and Hisatake, K. (2004) Mol. Cell. Biol. 24, 6525-6535 
20. Fukuda, A., Nogi, Y., and Hisatake, K. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 
1206-1211 
21. Fukuda, A., Yamauchi, J., Wu, S. Y., Chiang, C. M., Muramatsu, M., and Hisatake, K. 
(2001) Genes Cells 6, 707-719 
22. Hill, C. S., and Treisman, R. (1995) EMBO J. 14, 5037-5047 
23. Dunn, K. L., Espino, P. S., Drobic, B., He, S., and Davie, J. R. (2005) Biochem. Cell 
Biol. 83, 1-14 
24. Reason, A. J., Morris, H. R., Panico, M., Marais, R., Treisman, R. H., Haltiwanger, R. 
S., Hart, G. W., Kelly, W. G., and Dell, A. (1992) J. Biol. Chem. 267, 16911-16921 
25. Comerford, K. M., Leonard, M. O., Karhausen, J., Carey, R., Colgan, S. P., and Taylor, 
C. T. (2003) Proc. Natl. Acad. Sci. U. S. A. 100, 986-991 
26. Lipford, J. R., and Deshaies, R. J. (2003) Nat. Cell. Biol. 5, 845-850 
27. Ge, H., and Roeder, R. G. (1994) Cell 78, 513-523 
28. Kretzschmar, M., Kaiser, K., Lottspeich, F., and Meisterernst, M. (1994) Cell 78, 
525-534. 
29. Henry, N. L., Bushnell, D. A., and Kornberg, R. D. (1996) J. Biol. Chem. 271, 
21842-21847 
30. Malik, S., Gu, W., Wu, W., Qin, J., and Roeder, R. G. (2000) Mol. Cell 5, 753-760 
31. Reinberg, D., Horikoshi, M., and Roeder, R. G. (1987) J. Biol. Chem. 262, 3322-3330 
32. Hassfeld, W., Chan, E. K., Mathison, D. A., Portman, D., Dreyfuss, G., Steiner, G., and 
Tan, E. M. (1998) Nucleic Acids Res. 26, 439-445 
33. Flint, J., and Shenk, T. (1997) Annu. Rev. Genet. 31, 177-212 
34. Wysocka, J., and Herr, W. (2003) Trends Biochem. Sci. 28, 294-304 
 10 
35. Haviv, I., Vaizel, D., and Shaul, Y. (1996) EMBO J. 15, 3413-3420 
36. Haviv, I., Shamay, M., Doitsh, G., and Shaul, Y. (1998) Mol. Cell. Biol. 18, 1562-1569 
37. Damania, B., and Alwine, J. C. (1996) Genes Dev. 10, 1369-1381 
38. Haviv, I., Matza, Y., and Shaul, Y. (1998) Genes Dev. 12, 1217-1226 
39. Lukac, D. M., Harel, N. Y., Tanese, N., and Alwine, J. C. (1997) J. Virol. 71, 7227-7239 
40. Malik, S., and Roeder, R. G. (2005) Trends Biochem. Sci. 30, 256-263 
41. Mittler, G., Kremmer, E., Timmers, H. T., and Meisterernst, M. (2001) EMBO Rep. 2, 
808-813 
42. Baek, H. J., Malik, S., Qin, J., and Roeder, R. G. (2002) Mol. Cell. Biol. 22, 2842-2852 
43. Naar, A. M., Beaurang, P. A., Zhou, S., Abraham, S., Solomon, W., and Tjian, R. (1999) 
Nature 398, 828-832 
44. Zhu, H., and Pyrwes, R. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 5291-5295 
45. Wang, D., Chang, P. S., Wang, Z., Sutherland, L., Richardson, J. A., Small, E., Krieg, P. 
A., and Olson, E. N. (2001) Cell 105, 851-862 
46. Wang, D. Z., Li, S., Hockemeyer, D., Sutherland, L., Wang, Z., Schratt, G., Richardson, 
J. A., Nordheim, A., and Olson, E. N. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 
14855-14860 
47. Chan, H. M., and La Thangue, N. B. (2001) J. Cell Sci. 114, 2363-2373 
48. Iourgenko, V., Zhang, W., Mickanin, C., Daly, I., Jiang, C., Hexham, J. M., Orth, A. P., 
Miraglia, L., Meltzer, J., Garza, D., Chirn, G. W., McWhinnie, E., Cohen, D., Skelton, J., 
Terry, R., Yu, Y., Bodian, D., Buxton, F. P., Zhu, J., Song, C., and Labow, M. A. (2003) 
Proc. Natl. Acad. Sci. U. S. A. 100, 12147-12152 
49. Conkright, M. D., Canettieri, G., Screaton, R., Guzman, E., Miraglia, L., Hogenesch, J. 
B., and Montminy, M. (2003) Mol. Cell 12, 413-423 
50. Krecic, A. M., and Swanson, M. S. (1999) Curr. Opin. Cell Biol. 11, 363-371 
51. Huang, J., Li, S. J., Chen, X. H., Han, Y., and Xu, P. (2008) Cell. Mol. Biol. Lett. 13, 
303-311 
52. Michelotti, E. F., Michelotti, G. A., Aronsohn, A. I., and Levens, D. (1996) Mol. Cell. 
Biol. 16, 2350-2360 
53. Bomsztyk, K., Denisenko, O., and Ostrowski, J. (2004) Bioessays 26, 629-638 
54. Monsalve, M., Wu, Z., Adelmant, G., Puigserver, P., Fan, M., and Spiegelman, B. M. 
(2000) Mol. Cell 6, 307-316 
55. Auboeuf, D., Dowhan, D. H., Li, X., Larkin, K., Ko, L., Berget, S. M., and O'Malley, B. 
W. (2004) Mol. Cell. Biol. 24, 442-453 
56. Iwasaki, T., Chin, W. W., and Ko, L. (2001) J. Biol. Chem. 276, 33375-33383 
57. Carty, S. M., and Greenleaf, A. L. (2002) Mol. Cell. Proteomics 1, 598-610 
 
FOOTNOTES 
   We gratefully acknowledge the technical assistance of Michiyo Takeuchi.  We thank 
Robert G. Roeder for plasmids and Sohail Malik for antibodies and cell lines.  This work was 
supported in part by Grants-in-Aid for Scientific Research (to A.F. and K.H.) and Special 
Coordination Funds for Promoting Science and Technology (to A.F.) of the Ministry of 
Education, Culture, Sports, Science and Technology of Japan. 
 
The abbreviations used are: GTF, general transcription factor; TREF, transcriptional regulator of 
c-fos; RNAP II, RNA polymerase II; hnRNP R, heterogeneous nuclear ribonucleroprotein R; 
RRM, RNA recognition motif; RGG, arginine-glycine-glycine rich 
 
LEGENDS TO FIGURES 
FIGURE 1.  Expression and purification of the full-length activators for the c-fos gene.  A. 
Schematic diagram of the c-fos gene.  The regulatory cis-elements (SRE, FAP-1 and CRE) in 
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the c-fos promoter and their cognate activators (SRF, Elk-1, CREB and ATF1) are depicted in 
the diagram.  B. Purification schemes of SRF, Elk-1, CREB and ATF1.  Recombinant 
FLAG-tagged proteins were expressed in insect (High Five) cells, and their extracts were used 
for the following purification.  Three columns (HiTrap heparin, HiTrap Q and Mono S) were 
used for purification of SRF and Elk-1, while HiTrap SP and anti-FLAG M2 affinity resin were 
used for purification of CREB and ATF1.  C. SDS-PAGE analysis of purified activators.  
Purified activators (~1.0 mg) were resolved on a 10% SDS-polyacrylamide gel and stained with 
Coomassie Brilliant Blue. 
 
FIGURE 2.  Transcriptional activities of SRF, Elk-1, CREB and ATF1 in the reconstituted in 
vitro transcription system.  A. Schematic diagram of the templates used for in vitro 
transcription assays.  The c-fos template, pfMC2AT, contains the SRE, FAP-1, CRE and the 
TATA box, which are derived from the human c-fos promoter, together with a 390-nt G-less 
cassette.  The 5xG template, pG5HMC2AT, contains five GAL4-binding sites, the HIV-1 
TATA box and a 390-nt G-less cassette.  The control plasmid, pMLΔ53C2AT, containing the 
Ad2MLP-derived TATA box and a 290-nt G-less cassette, was used for measuring basal 
transcription as a control.  B. In vitro transcription assays in the absence of coactivators.  
Transcription reactions were performed in a reconstituted system consisting of GTFs and RNAP 
II with the indicated recombinant activator.  The amounts of activators were 5, 20 or 80 ng for 
SRF, CREB and ATF1, and 2.5, 10 or 40 ng for Elk-1.  The arrow and arrowhead indicate the 
positions of the transcripts from activator-dependent (pfMC2AT) and basal transcription 
(pMLΔ53C2AT), respectively, and the relative levels of activator-dependent transcription are 
shown below each lane.  C. In vitro transcription assays were done with various combinations 
of the activators.  The relative levels of activator-dependent and basal transcription are shown 
below each lane.  D. GAL4-VP16-dependent transcription using pG5HMC2AT.  The 
reactions contained 1.6, 6.3 or 25 ng of GAL4-VP16.  The arrow indicates the transcripts from 
activator-dependent transcription (pG5HMC2AT). 
 
FIGURE 3.  Effect of coactivator PC4 on transcriptional activation by SRF, Elk-1, CREB and 
ATF1.  A. PC4 (200 ng) was added to the in vitro transcription reactions containing one of the 
activators (SRF, Elk-1, CREB and ATF1).  The positions of the transcripts from 
activator-dependent (arrow) and basal (arrowhead) transcription are indicated on the right.  B. 
PC4 (200 ng) was added to the in vitro transcription reactions with various combinations of SRF, 
Elk-1, CREB and ATF1 as activators.  C. PC4 (200 ng) was added to in vitro transcription 
reactions from pG5HMC2AT with GAL4-VP16 as an activator.  The arrow indicates 
activator-dependent transcription from pG5HMC2AT.  D. Interactions of PC4 with SRF, Elk-1, 
CREB, ATF1 and VP16.  GST-fused activators were immobilized on Glutathione Sepharose 
4B and incubated with FLAG-PC4.  The bound proteins were eluted in high salt buffer and 
analyzed by immunoblot analysis using anti-FLAG M2 antibody.  The position of FLAG-PC4 
is indicated by an arrow on the right. 
 
FIGURE 4.  A novel activity enhances transcription from the c-fos promoter.  A. Fractionation 
scheme of HeLa nuclear extract.  HeLa nuclear extract was fractionated stepwise by P11 (0.1, 
0.3, 0.5, 0.85M KCl) and the derived fraction was further fractionated by DE52 (0.1, 0.3M KCl) 
into 8 fractions.  The names of the DE52-derived fractions are as indicated at the bottom.  B. 
In vitro transcription assays.  Each fraction was added to the in vitro transcription reactions 
using the c-fos template, pfMC2AT, in the presence or absence of the activators (SRF, Elk-1, 
CREB and ATF1).  PC4 was also added with the activators.  C. Effect of varying amounts of 
purified TFIIA or TFIID on c-fos transcription. 
 
FIGURE 5.  Promoter specificity of TREF and its cooperativity with Mediator.  A. A novel 
coactivator activity, TREF, is specific to the c-fos promoter.  In vitro transcription was 
performed using the c-fos template (pfMC2AT) or 5xG template (pG5HMC2AT) in the presence 
or absence of the activators (SRF, Elk-1, CREB, ATF1 and PC4 for pfMC2AT; GAL4-VP16 and 
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PC4 for pG5HMC2AT).  Either A0.3 or D0.1 fraction was added to the indicated reactions.  
The arrow indicates the transcripts from pfMC2AT (lanes 1-6) or pG5HMC2AT (lanes 7-12).  
B. Purification of Mediator.  The nuclear extract from the HeLa cell line that expresses 
FLAG-tagged Nut2 (F:Nut2) was fractionated by P11, and Mediator was purified from the 0.85 
M KCl fraction using anti-FLAG M2 affinity gel.  C. TREF cooperates with Mediator in 
activating transcription from the c-fos promoter.  TREF and Mediator were added to the 
transcription reactions and the positions of transcripts from pfMC2AT and pMLΔ53C2AT are 
indicated by arrow and arrowhead, respectively. 
 
FIGURE 6.  hnRNP R stimulates transcription from the c-fos promoter.  A. Purification 
scheme of TREF activities.  The TREF activity (A0.3) was further purified by Q Sepharose, 
Heparin Sepharose and Mono S columuns, and separated into three chromatographically distinct 
activities designated TREFα, TREFβ and TREFγ.  B. Transcriptional activities of the Mono S 
fractions of TREFα were assayed using pfMC2AT in the presence of SRF, Elk-1, CREB, ATF1 
and PC4.  The corresponding fractions were analyzed by SDS-PAGE and silver staining.  The 
position of a ~80 kDa protein that correlated with the transcriptional activity is indicated on the 
right.  C. Structural domains of hnRNP R.  RRM, NLS and RGG indicate the RNA 
recognition motif, nuclear localization signal and argnine-glycine-glycine-rich domain, 
respectively.  The regions rich in acidic amino acids or in glutamine and asparagine is 
indicated by acidic or QN, respectively.  D. Purification of recombinant hnRNP R.  
FLAG-tagged hnRNP R was expressed in insect cells and purified by SP Sepharose, Q 
Sepharose and anti-FLAG M2 agarose.  The purified hnRNP R was analyzed by SDS-PAGE.  
Transcriptional activity of hnRNP R was tested in the transcription assays using pfMC2AT, in 
which the presence of SRF, Elk-1, CREB, ATF1 and PC4 is indicated by +.  Relative levels of 
activator-dependent transcription from pfMC2AT are indicated below the panel.  E. hnRNP R, 
PC4 and Mediator were added in various combinations to the transcription reactions containing 
SRF, Elk-1, CREB and ATF1 as activators.  Relative levels of activator-dependent transcription 
from pfMC2AT are indicated below the panel. 
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